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Abstract
Disorders or differences in sex development (DSD) comprise a heterogeneous group of conditions with an atypical 
sex development. For optimal diagnosis, highly specialised laboratory analyses are required across European 
countries. Working group 3 of EU COST (European Cooperation in Science and Technology) Action BM 1303 ‘DSDnet’ 
‘Harmonisation of Laboratory Assessment’ has developed recommendations on laboratory assessment for DSD 
regarding the use of technologies and analytes to be investigated. This position paper on steroid hormone analysis 
in diagnosis and treatment of DSD was compiled by a group of specialists in DSD and/or hormonal analysis, either 
from participating European countries or international partner countries. The topics discussed comprised analytical 
methods (immunoassay/mass spectrometry-based methods), matrices (urine/serum/saliva) and harmonisation of 
laboratory tests. The following positions were agreed upon: support of the appropriate use of immunoassay- and 
mass spectrometry-based methods for diagnosis and monitoring of DSD. Serum/plasma and urine are established 
matrices for analysis. Laboratories performing analyses for DSD need to operate within a quality framework and 
actively engage in harmonisation processes so that results and their interpretation are the same irrespective of the 
laboratory they are performed in. Participation in activities of peer comparison such as sample exchange or when 
available subscribing to a relevant external quality assurance program should be achieved. The ultimate aim of the 
guidelines is the implementation of clinical standards for diagnosis and appropriate treatment of DSD to achieve the 
best outcome for patients, no matter where patients are investigated or managed.
Introduction
Disorders or differences in sex development (DSD) 
comprise a heterogeneous group of conditions with 
an atypical sex development. Patients with DSD are 
complex and rare, and multi-disciplinary teams are 
needed for optimal diagnosis and management. Thus, 
highly specialised laboratory analyses are required across 
European countries. COST (European Cooperation 
in Science and Technology) Action ‘DSDnet’ forms a 
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network bringing together different stakeholders and 
people interested in DSD, scientists, clinicians as well 
as people with DSD (www.dsdnet.eu). Working group 
3 ‘Harmonisation of Laboratory Assessment’ of the 
COST action ‘DSDnet’ has developed recommendations 
on laboratory assessment for DSD regarding the use 
of technologies and analytes to be investigated. This 
important work will form the basis of future European 
reference network for rare endocrine disorders. This 
position paper on steroid hormone analysis in diagnosis 
and treatment of DSD was compiled by a group of 
specialists in DSD and/or hormonal analysis, either 
from participating European countries or international 
partner countries.
Relevance of clinical steroid analysis
The Chicago consensus statement and recent literature 
regarding disorders of sex development emphasises the 
need for comprehensive diagnosis and treatment of DSD 
(1, 2, 3, 4, 5). Diagnosis of DSD remains challenging for 
involved paediatricians, endocrinologists, geneticists, 
urologists and other related disciplines, as even with novel 
approaches a specific molecular diagnosis is only achieved 
in about 30–50% of patients with 46,XY DSD (4). Thus, 
the diagnostic pathway in patients with DSD requires 
close interlinking between the clinical, biochemical and 
genetic diagnostic work-up.
Traditionally, hormonal analyses in blood or urine 
have been used as part of the first-line diagnostic 
approach (Fig.  1). In current practice, this is more 
frequently used in combination with molecular genetic 
analyses. In addition to diagnostic data, biochemical 
analysis will provide additional functional information 
guiding further management, disease monitoring and 
explain differences in phenotypic expression. However, 
this heavily depends on local and national diagnostic 
pathways and regional differences in accessibility to highly 
specialised analyses. There are significant differences 
in funding streams, clinical and laboratory resources as 
well as the interplay with research laboratories, resulting 
in a heterogeneous situation in Europe. In many 
countries, clinical endocrinology has increasingly become 
dominated by economic constraints. Although hormone 
measurement has traditionally been a mainstay of clinical 
endocrinology, the absorption of hormone labs by 
centralised laboratory units is associated with the risk of 
loss of expertise in hormone test development, selection 
and data interpretation. A Pan-European and ultimately 
a global approach should aim for a harmonisation of 
diagnostic pathways according to requirements achieving 
the correct diagnosis.
The majority of 46,XX infants presenting with 
virilisation of the external genitalia will have congenital 
adrenal hyperplasia (CAH). In such cases, a quantification 
of multiple steroids in a steroid profile is very important 
to detect rare forms of steroid biosynthesis disorders. 
A recent report on exome sequencing exemplifies 
the significant benefit of next-generation sequencing 
techniques for diagnosing 46,XY DSD (4). However, the 
paper indirectly illustrates the requirement of detailed 
clinical and comprehensive biochemical data for a holistic 
understanding of individual DSD cases.
Hormonal analysis (6) is not only important for the 
initial diagnosis of DSD. It also remains a decisive corner 
stone for monitoring adequate hormone replacement 
in various conditions with the goal of avoiding adrenal 
crises, ensuring optimal development of growth, 
weight and puberty, supporting sexual function and 
optimising quality of life in patients with DSD. It is of 
paramount importance that any meaningful hormone 
data interpretation in relation to DSD has to take into 
consideration the patient’s individual clinical picture 
and requires age- and sex-specific reference intervals due 
to the changing physiology of the developing child and 
young person (7, 8, 9, 10).
Advantages of clinical steroid analysis
Clinical steroid profiling remains an important first-line 
approach to the diagnosis of DSD, as it provides fast 
and comprehensive results and thus allows for a rapid 
differential diagnostic orientation. In cases of CAH, it has 
a good phenotype–genotype correlation (11).
Challenges of clinical steroid analysis
Over the course of recent years, it has become increasingly 
difficult to recruit healthy volunteers in childhood and 
adolescence to establish normative reference data from a 
control cohort. This is mainly the result of ethical concerns 
and prevents the implementation of accurate age- and sex-
specific reference intervals. Soeborg et al. (10) emphasise 
that medical treatment, such as exogenous steroids, 
hepatic metabolism-interacting agents or liquorice-
containing sweets can influence steroid metabolism and 
may influence the interpretation of results (12). Recent 
studies also describe an impact of nutritional status on 
steroid hormone concentrations (13). This indicates 
that there is an ongoing need for establishing reference 
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intervals. However, through the harmonisation of 
laboratory tests, there is the potential to develop common 
reference intervals. The work required to generate these 
data should be shared thus allowing results from different 
laboratories to be directly compared.
Analytical methods
The main aim of clinical guidelines is to implement 
clinical standards for diagnosis and appropriate treatment 
to achieve the best outcome for patients, no matter 
Figure 1
Synthesis and metabolism of hormonal steroids. This figure illustrates the formation of the major hormone classes from 
cholesterol. Steroid names in conventional script are steroid hormones and precursors; those in italics are urinary metabolites of 
the aforementioned. The major transformative enzymes are in rectangular boxes, the cofactor (‘facilitator’) enzymes in ovals. 
Mitochondrial CYP type I enzymes requiring electron transfer via adrenodoxin reductase (ADR) and adrenodoxin (Adx) CYP11A1, 
CYP11B1 and CYP11B2 are marked with a labelled box ADR/Adx. Microsomal CYP type II enzymes receive electrons from P450 
oxidoreductase (POR), CYP17A1, CYP21A2, CYP19A1 and are marked by circled POR. The 17,20-lyase reaction catalysed by 
CYP17A1 requires in addition to POR also cytochrome b5 indicated by a circled b5. Similarly, hexose-6-phosphate dehydrogenase 
(H6PDH) is the cofactor-generating enzyme for 11β-HSD1 (HSD11B1). The asterisk (*) indicates the 11-hydroxylation of 
17-hydroxyprogesterone to 21-deoxycortisol in 21-hydroxylase deficiency. The conversion of androstenedione to testosterone is 
catalysed by HSD17B3 in the gonad and AKR1C3 (HSD17B5) in the adrenal. CYP11A1, P450side-chain cleavage enzyme; CYP11B1, 
11β-hydroxylase; CYP11B2, aldosteronesynthase; CYP17A1, 17α-hydroxylase/17,20-lyase; CYP21A2, 21-hydroxylase; HSD3B2, 
3β-hydroxysteroid dehydrogenase type 2; HSD11B1, 11β-hydroxysteroid dehydrogenase type 1; HSD11B2, 11β-hydroxysteroid 
dehydrogenase type 2; HSD17B, 17β-hydroxysteroid dehydrogenase; PAPSS2, 3′-phosphoadenosine 5′-phosphosulfate synthase 2; 
SRD5A2, 5α-reductase type 2; StAR, steroidogenic acute regulatory protein; SULT2A1, sulfotransferase 2A1.
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where patients are investigated or managed. Therefore, 
all methods require appropriate validation to ensure 
that they are fit for their intended clinical purpose (14). 
This includes the important peer comparison processes 
of sample exchange or, if available, participation in an 
external quality assurance scheme (EQA).
Immunoassay methods
The principle of all immunoassay-based methods is the 
binding of an antigen to an antibody. In the late 1970s, 
the radioligands were replaced with chemiluminescence, 
enzymatic or fluorescent ligands. In general, 
immunoassay-based methods for steroid measurements 
detect a tracer rather than directly the analyte. Most 
clinical biochemistry laboratories adopted these assays 
due to their low cost, simplicity and fast turn-around 
times. Immunoassays are available for various steroidal 
analytes as commercial kits on automated platforms. One 
advantage of radio immunoassay (RIA) methods is the 
wide and extensive experience as these assays have been 
used for almost 50 years in clinical routine and research 
laboratories. During this time, a considerable amount 
of data have been accumulated, and numerous studies 
have enriched the field of endocrinology (15). For some 
analytes such as estradiol, very sensitive techniques exist 
(16, 17). Thus, immunoassays can produce highly specific 
results, particularly in combination with preceding 
extraction and/or chromatography of the samples (18). 
Improved separation through extraction is particularly 
important for newborns, especially if born early, as the 
fetal adrenal zone that produces a different mix of steroids 
persists until at least the equivalent of term (19).
However, numerous commercial assays, especially 
automated immunoassays, have recently been shown 
to have impaired specificity due to cross-reactivity of the 
antibody and other unidentified interferences from the 
matrix (20, 21). Therefore, tests evaluated in serum/plasma 
from healthy adults do not necessarily produce reliable 
values in neonates or pregnant women (22) or when 
applied in different matrices such as saliva or urine. The 
rapid analysis time in many high-throughput analytical 
platforms may also be observed at the expense of poorer 
sensitivity (detection limit). Furthermore, immunoassays 
can only measure one steroid per analysis. Thus, larger 
volumes of serum/plasma are required for analysis. 
This can be particularly challenging when measuring 
small-volume samples from newborns and infants. The 
use of radioactivity in RIAs requires special laboratory 
facilities and generates radioactive waste. The lack of 
standardisation of immunoassays represents a major 
problem for the comparability of laboratory results, and 
in many cases, method-specific reference intervals must 
be considered for interpretation. In the current European 
landscape, immunoassays are still commonly employed for 
steroid hormone analysis. However, in the light of future 
developments, it can be expected that immunoassays 
will increasingly be replaced by mass spectrometry-based 
methods.
Mass spectrometry-based methods
Mass spectrometry-based steroid hormone assays are 
physicochemical analytical techniques identifying the 
analyte by determining typical mass-to-charge ratios 
of the respective molecule or its typical fragments. In 
contrast to conventional isotopic and non-isotopic 
immunoassay techniques, mass spectrometry allows 
for higher specificity (23). Liquid chromatography 
linked with tandem mass spectrometry (LC–MS/MS) 
enables targeted steroid hormone analysis of multiple 
analytes from a single sample (9, 10, 24, 25, 26, 27). Gas 
chromatography coupled with mass spectrometry (GC–
MS) allows for the simultaneous determination of steroid 
hormones and metabolites within targeted as well as non-
targeted approaches.
At first glance, mass spectrometry-based 
methods may appear rather costly due to the price 
of sophisticated instrumentation, maintenance 
of equipment and the need for qualified personal 
operating the instruments. However, in comparison 
to other diagnostic procedures, such as molecular 
genetics, imaging procedures (computed tomography, 
magnetic resonance imaging and isotope-based 
imaging techniques) or multiple immunoassays, 
hormone profiling by mass spectrometry is actually 
very cheap. The use of LC–MS/MS for steroid analysis is 
still challenging. One of the main complicating factors 
in mass spectrometric steroid analysis is the presence of 
isobaric interferences caused by ions of identical mass-
to-charge ratio and similar fragmentation patterns (28). 
Although steroid analysis by LC–MS/MS is becoming 
increasingly available for routine use, validation and 
quality control present important future challenges 
(29). Reference intervals are not widely available and in 
contrast to earlier anticipation these are considerably 
dependent on individual specific laboratory settings, 
such as sample work-up and/or instrumentation.
PROOF ONLY
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
176:5 P5Position Statement A Kulle and others Position paper EU COST Action 
BM 1303 ‘DSDnet’
www.eje-online.org
Analytical matrices
Blood (serum vs plasma), urine and saliva (30, 31) are 
the biomaterials (i.e. matrices) most commonly used for 
clinical steroid hormone analysis. Saliva is less broadly 
established, and few studies on steroids analysed in 
saliva exist for the differential diagnosis of DSD, and the 
working group does not have a stance for or against the 
inclusion of this matrix currently. It is recommended 
that clinicians contact their laboratories in advance to 
follow their recommendations regarding appropriate 
type of sample as well as mode of shipment (32, 33, 34).
Harmonisation of laboratory tests
Initiatives in laboratory medicine that support 
harmonisation stem from Europe and are now being 
embraced globally. Bias, imprecision and interferences 
can all lead to erroneous results. As such, method 
validation is fundamental in establishing the extent and 
acceptability of each of these studies for clinical diagnostic 
assays to ensure that they operate within an accepted 
quality framework. Although each of these validation 
parameters is important, minimisation of bias is essential 
for harmonisation.
Harmonisation and, where practical, standardisation 
with traceability, are enormous challenges (35). The process 
has been described in terms of five supporting pillars, 
these are aimed at establishing: (1) certified reference 
materials (CRM); (2) reference measurement procedures 
(RMP); (3) reference laboratories; (4) participation in an 
EQA program and (5) reference intervals and decision 
limits (36).
In principle, full standardisation with traceability 
should be achievable for all steroids as they are small 
compounds of defined molecular weight. The Joint 
Committee for Traceability in Laboratory Medicine 
(JCTLM) was established in 2002 to support this process 
worldwide through the development of a database to 
recognise primary reference materials, methods and 
laboratories (www.bipm.org/jctlm. Accessed 19th June 
2016). This JCTLM database, which is hosted by the 
Bureau International of Weights and Measures (BIPM) 
(Sevres Cedex, France), currently lists some (e.g. serum 
cortisol, oestradiol, progesterone and testosterone) but 
not all steroids important for the assessment of DSD 
(e.g. serum 17-hydroxyprogesterone, androstenedione, 
cortisone and dihydrotestosterone).
Participation in an EQA program is generally 
recognised to be the central pillar as it provides the 
framework for objective comparison of the result 
obtained by many laboratories for the one sample 
(37, 38). However, to proceed down this pathway for the 
harmonisation of laboratory assessment, we first need to 
establish a collaborative agreement on the analytes and 
their matrices that should be measured for the differential 
diagnosis of a DSD. Recently, a first EQA program for the 
harmonisation of serum dihydrotestosterone analysis has 
been launched (39).
Steroid analysis in conditions associated 
with DSD
46,XX DSD conditions
21-Hydroxylase deficiency
CAH due to 21-hydroxylase deficiency (21OHD) is 
the most common cause of DSD in 46,XX individuals 
(40). Due to overproduction of androgens, 46,XX 
individuals usually present with ambiguous genitalia 
without palpable gonads. The condition is treated with 
glucocorticoids and if required mineralocorticoids. 
In serum/plasma, 17-hydroxyprogesterone and 
21-deoxycortisol with or without ACTH stimulation 
Position 1: Although mass spectrometry is purported 
to be a superior technique, it is not available for all 
hormones and is currently not a realistic analytical 
option in all regions of Europe. Our position is 
therefore to support the appropriate use of both 
immunoassay and mass spectrometry-based methods 
for the diagnosis and monitoring of DSD. It is essential 
that clinicians should also know the characteristics 
and limitations of analytical methods used.
Position 2: Both, serum/plasma and urine, are 
established matrices for analysis for steroids and 
dependent on the specific DSD condition under 
consideration, analysis of steroids in either matrix 
may be appropriate.
Position 3: Laboratories should aim to participate 
in activities of peer comparison such as a sample 
exchange or preferably when available subscribe to a 
relevant external quality assurance program.
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(adrenocorticotropic hormone) are the indicative 
diagnostic parameters for 21OHD. Usually, no ACTH 
stimulation is required in classic CAH. Urinary steroid 
profile analysis, a non-invasive means, also allows 
for definitive diagnosis: 17-hydroxypregnanolone, 
pregnanetriol and pregnanetriolone are the key diagnostic 
urinary metabolites (41). Steroid monitoring of 21OHD 
is performed by the determination of the previously 
mentioned hormones and their metabolites in either 
serum, plasma, urine or saliva (42).
11β-Hydroxylase deficiency
It is characterised by elevated serum/plasma 
11-deoxycortisol and deoxycorticosterone. Individuals 
with 46,XX DSD suffering from 11β-hydroxylase 
deficiency also present with virilisation of the external 
genitalia. The onset of hyporeninemic, hypokalaemic 
hypertension is variable. The urinary steroid profile is 
dominated by elevated tetrahydro-11-deoxycortisol (43).
3β-Hydroxysteroid dehydrogenase deficiency (3βHSDD)
This condition is clinically characterised by 
undermasculinisation in 46,XY individuals and 
virilisation in 46,XX individuals (44). The pathognomonic 
hormonal pattern is characterised by the elevation of 
17-hydroxypregnenolone, dehydroepiandrosterone 
(DHEA) and dehydroepiandrosterone sulphate (DHEAS) 
in serum/plasma and increased excretion rates of 
their corresponding urinary metabolites including 
androstenetriol.
Cytochrome P450 (P450) oxidoreductase deficiency
This condition presents biochemically as combined 
17-hydroxylase/lyase and 21-hydroxylase deficiency. It 
is caused by a defect of the electron-donating protein 
to microsomal P450 type 2 enzymes. The typical 
presentation is a child with ambiguous genitalia and 
Antley–Bixler syndrome; however, a wide spectrum of 
clinical presentations has been described (45).
46,XY-DSD conditions
Steroid acute regulatory protein (StAR) deficiency and 
P450 side chain cleavage enzyme (P450scc) deficiency
StAR deficiency leads to lipoid CAH, whereas deficiency 
of P450scc commonly leads to small adrenals. Both 
conditions present with similar clinical appearance. 
Only a few patients might have a severe salt loss 
crisis in the first months of life. The majority of 
46,XY individuals show undervirilisation or complete 
feminisation. In 46,XX patients, no further clinical 
features might be present in the first months of life. 
Typically, glucocorticoids, mineralocorticoids and sex 
steroids are all low to undetectable. Treatment with 
glucocorticoids (e.g. hydrocortisone) and later with sex 
hormones should be monitored by determining the 
respective steroids (46).
17-Hydroxylase/17,20 lyase deficiency
Typically, 17-deoxygenated steroids, e.g. corticosterone, 
are elevated, whereas 17-oxygenated steroids, such 
as cortisol and sex steroids, are markedly reduced or 
absent in serum/plasma. Urinary steroid profile analysis 
likewise reflects an increase in 17-deoxygenated over 
17-oxygenated metabolites (47). Patients are clinically 
often glucocorticoid replete despite impaired cortisol 
synthesis as corticosterone excess with its glucocorticoid 
action is compensating for the lack of cortisol. The 
deficiency of sex hormone biosynthesis is causing DSD 
in these individuals. All affected individuals (46,XY 
and 46,XX) with complete deficiency classically fail 
to develop secondary sexual characteristics. Similar to 
11β-hydroxylase deficiency, the onset of hyporeninemic, 
hypokalaemic hypertension is highly variable. 
Cytochrome P450 (P450) oxidoreductase deficiency
See section on 46,XX DSD conditions.
3βHSDD
See section on 46,XX DSD conditions.
5α-Reductase deficiency
Patients with mutations in the 5α-reductase type 2 gene 
usually show undermasculinisation at birth. Usually 
there is some degree of masculinisation at puberty due 
to increasing concentrations of testosterone. Diagnosis 
can be established using the ratio of testosterone to 
dihydrotestosterone in serum/plasma before and after 
hCG (human chorionic gonadotropin) stimulation 
(48, 49). The diagnosis can also be made by assessing the 
ratio between 5α- and 5β-reduced steroids in the urinary 
steroid profile (50).
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17β-Hydroxysteroid dehydrogenase type 3 deficiency
Due to the lack of testosterone during male sex 
differentiation, 46,XY children are often born with 
almost female-appearing external genitalia (51). In serum/
plasma, the ratio of androstenedione/testosterone after 
hCG stimulation is elevated. Urine steroid metabolomic 
profiling for this enzyme deficiency might not always be 
indicative for this gonadal enzyme defect.
Conclusions
As DSD represents a very heterogeneous and highly 
complex group of conditions, the integration of clinical, 
biochemical and genetic diagnostic approaches is required. 
The knowledge of steroid hormone biosynthesis is vital in 
understanding the pathogenesis of the specific condition. 
Furthermore, monitoring strategies of these entities 
are to a great extent based on biochemical parameters. 
Therefore, only most reliable methods are required. To 
achieve this aim, laboratories performing analyses for 
DSD need to operate within a quality framework and 
actively engage in harmonisation processes so that results 
and their interpretation are the same irrespective of the 
laboratory they are performed in.
However, the situation with respect to access to 
analytical technologies is very heterogeneous within 
Europe. This is due to essential differences in health 
care systems, modes of payment, different economical 
coverage and structure of biochemical services. This 
compromises the development of common strategies for 
Pan-European diagnosis and follow-up in DSD.
There is an urgent demand for establishing a network 
of highly specialised endocrine reference laboratories with 
expertise in DSD. These centres should have the required 
knowledge of analytical techniques, should have age- and 
sex-specific reference intervals to provide normative data 
and should provide experience with proper interpretation 
of values. It is essential to maintain and support existing 
laboratories with expertise in DSD. Therefore, the area 
of DSD also holds a deep political dimension. Interested 
parties are encouraged to contact head of working group 3 
for setting up a network of suitable reference laboratories. 
Investments to create and maintain such reference centres 
of expertise are vital to achieving a Pan-European and 
ultimately a global landscape ensuring access to optimal 
laboratory assessment for DSD.
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